Combination studies of CBP501, platinum-based anticancer drugs and immuno-oncology drugs
First written in FY2017-Q1. 17 of 34 entries say "Restated". Latest entry: 2026-10-14.
2 other companies' latest entry also says "Advanced".
- 2026-10-14AdvancedShare Issuance and Disposal
「欧州におけるCBP501臨床第3相試験は、現在欧州規制当局EMAとの間で臨床試験開始申請の手続を進めている途上であり、当局からの指導等によって今後変更の可能性がありますが、現時点で開始承認取得を見込んでいる概要は次のとおりです。」
CBP501と併用薬を用いる欧州第3相試験について、対象疾患、試験形式、被験者数および主要評価項目を含む計画概要と資金使途を具体化している。 - FY2026SoftenedAnnual report
「Through the results of clinical trials conducted to date and detailed analyses of the data, the company obtained findings indicating that combining CBP501 and cisplatin with an immune checkpoint inhibitor antibody enhances efficacy. Based on these findings, the company plans to make the combination the main focus of CBP501 development for the time being.」
The company continues to pursue a strategy centered on triple-combination therapy for the development of CBP501, but does not specify the concrete stage referenced in the immediately preceding half-year filing, namely the application for and preparations for a Phase 3 trial in Europe. - FY2026-H1RestatedAnnual report
「Clinical trials of CBP501 are being conducted in combination with an immune checkpoint inhibitor antibody, and the company is currently at the submission and preparation stage for a Phase 3 clinical trial in Europe.」
The company continues to develop CBP501 in combination with immune checkpoint inhibitor antibodies and reconfirms that it is applying and preparing for a European Phase 3 trial. - FY2025-H1RestatedAnnual report
「Clinical trials combining CBP501 with immune checkpoint inhibitor antibodies are underway, and in both the United States and Europe the company is currently applying and preparing for the next phase of clinical trials.」
The company continues to develop CBP501 in combination with immune checkpoint inhibitor antibodies and reconfirms that it is applying and preparing for the next phase of clinical trials in the United States and Europe. - FY2024AdvancedAnnual report
「The company has successfully completed the Phase 2 clinical trial of the three-drug combination and is preparing for the next phase of clinical development.」
Development of the three-drug combination of CBP501, cisplatin and an immune checkpoint inhibitor antibody has completed the Phase 2 trial and progressed to preparations for the next phase. - FY2024-Q3AdvancedAnnual report
「Clinical trials combining CBP501 with immune checkpoint inhibitor antibodies are underway, and in both the United States and Europe the company is currently applying and preparing for the next phase of clinical trials.」
Development of CBP501 in combination with an immune checkpoint inhibitor antibody has progressed to the application and preparation stage for a U.S. Phase 2b trial and a European Phase 3 trial. - FY2024-Q1RestatedAnnual report
「Clinical trials combining CBP501 with immune checkpoint inhibitor antibodies are underway, and preparations are currently being made for the next clinical trial.」
The company continues to develop CBP501 in combination with immune checkpoint inhibitor antibodies and reconfirms that it is preparing for the next clinical trial. - FY2023SoftenedAnnual report
「Data from previous trials showed that combining the treatment with immunotherapeutic anticancer drugs could enhance efficacy. The company is currently conducting a Phase 2 clinical trial in combination with an immune checkpoint inhibitor antibody for pancreatic cancer while preparing for the next phase of clinical development.」
Development of CBP501 in combination with cisplatin and an immune checkpoint inhibitor antibody is continuing, but unlike the previous quarter's filing, there is no explicit reference to preparations for a Phase 3 trial; the wording now refers to preparations for the next phase. - FY2023-Q3RestatedAnnual report
「Clinical trials combining CBP501 with immune checkpoint inhibitor antibodies are underway, and preparations are currently being made for a Phase 3 clinical trial.」
The company continues to develop CBP501 in combination with immune checkpoint inhibitor antibodies and reconfirms that it is preparing for a Phase 3 trial. - FY2023-Q2AdvancedAnnual report
「The trial achieved its primary endpoint in the three-drug combination arm including CBP501, and the Company decided to end the trial early after the first stage of its two-stage design. Preparations are currently under way to begin a Phase 3 clinical trial.」
The Phase 2 trial of the three-drug combination including CBP501 achieved its primary endpoint, completed the first stage early and progressed to preparations for a Phase 3 trial. - FY2023-Q1AdvancedAnnual report
「The company is conducting a clinical trial combining CBP501 with an immune checkpoint inhibitor antibody and is currently in the early stage of the Phase 2 clinical trial.」
The combination development of CBP501 and an immune checkpoint inhibitor antibody reached the stage of dosing and observation after completion of subject enrolment in the first stage of the Phase 2 trial. - FY2022RestatedAnnual report
「Through the results of clinical trials conducted to date and detailed analyses of the data, the company obtained findings indicating that combining CBP501 and cisplatin with an immune checkpoint inhibitor antibody enhances efficacy. Based on these findings, the company plans to make the combination the main focus of CBP501 development for the time being.」
The company continues its policy of making the combination of CBP501, cisplatin and an immune checkpoint inhibitor antibody the main focus of CBP501 development. - FY2022-Q3RestatedAnnual report
「The company is conducting a clinical trial combining CBP501 with an immune checkpoint inhibitor antibody and is currently in the early stage of the Phase 2 clinical trial.」
The company continues development of the combination of CBP501 and an immune checkpoint inhibitor antibody and reconfirmed that it is in the early stages of the Phase 2 clinical trial. - FY2022-Q2RestatedAnnual report
「The company is conducting a clinical trial combining CBP501 with an immune checkpoint inhibitor antibody and is currently in the early stage of the Phase 2 clinical trial.」
The company continues development of the combination of CBP501 and an immune checkpoint inhibitor antibody and reconfirmed that it is in the early stages of the Phase 2 clinical trial. - FY2022-Q1AdvancedAnnual report
「For CBP501, the company is conducting a clinical trial of the combination with an immune checkpoint inhibitor antibody, specifically the Phase 1b expansion phase, while also beginning the Phase 2 clinical trial.」
The company advanced the Phase 1b expansion phase of the combination of CBP501 and an immune checkpoint inhibitor antibody to its final stages and began the Phase 2 clinical trial in parallel. - FY2021AdvancedAnnual report
「The company is advancing a clinical trial combining CBP501 with cisplatin and the immune checkpoint inhibitor antibody nivolumab, namely the Phase 1b expansion phase, while in parallel preparing for a Phase 2 clinical trial.」
The company advanced the combination trial of CBP501 and an immune checkpoint inhibitor antibody to its final stages and moved to the preparation stage for the Phase 2 clinical trial. - FY2021-Q3RestatedAnnual report
「Based on these findings, the company is currently conducting a Phase 1b clinical trial of the combination with an immune checkpoint inhibitor antibody, specifically the expansion phase.」
The company continues its policy of conducting the Phase 1b expansion phase of the combination of CBP501 and an immune checkpoint inhibitor antibody and preparing for the Phase 2 clinical trial. - FY2021-Q2AdvancedAnnual report
「Based on these findings, the company is currently conducting a Phase 1b clinical trial of the combination with an immune checkpoint inhibitor antibody, specifically the expansion phase, while also preparing for the next clinical trial phase.」
The combination trial of CBP501 and an immune checkpoint inhibitor antibody completed dosing in the expansion phase and progressed to the preparation stage for the next clinical trial phase. - FY2021-Q1AdvancedAnnual report
「Based on these findings, the company is currently conducting a Phase 1b clinical trial of the combination with an immune checkpoint inhibitor antibody, specifically the expansion phase.」
The combination trial of CBP501 and an immune checkpoint inhibitor antibody entered its final stages of the expansion phase, and enrolment for the target cancer types was completed. - FY2020RestatedAnnual report
「Through the results of clinical trials conducted to date and detailed analyses of the data, the company obtained findings indicating that combining CBP501 and cisplatin with an immune checkpoint inhibitor antibody enhances efficacy. Based on these findings, the company plans to make the combination the main focus of CBP501 development for the time being.」
The company reconfirmed its policy of making the combination of CBP501, cisplatin and an immune checkpoint inhibitor antibody the main focus of CBP501 development. - FY2020-Q3RestatedAnnual report
「Analyses of data from previous clinical trials produced findings suggesting that CBP501 exhibits anticancer activity by acting on various areas, including cancer immunity and the tumour microenvironment, through modulation of calmodulin function. The company also worked to obtain animal study data and other information on the combination of CBP501, a platinum-based anticancer agent and an immuno-oncology agent. Based on these newly obtained findings, the company is currently conducting a Phase 1b clinical trial of the combination with an immune checkpoint inhibitor antibody.」
The company continues research on combinations of CBP501, platinum-based anticancer agents and immuno-oncology agents, as well as the combination trial with an immune checkpoint inhibitor antibody based on those findings. - FY2020-Q2RestatedAnnual report
「Analyses of data from previous clinical trials produced findings suggesting that CBP501 exhibits anticancer activity by acting on various areas, including cancer immunity and the tumour microenvironment, through modulation of calmodulin function. The company also worked to obtain animal study data and other information on the combination of CBP501, a platinum-based anticancer agent and an immuno-oncology agent. Based on these newly obtained findings, the company is currently conducting a Phase 1b clinical trial of the combination with an immune checkpoint inhibitor antibody.」
The company continues research on combinations of CBP501, platinum-based anticancer agents and immuno-oncology agents, as well as the combination trial with an immune checkpoint inhibitor antibody based on those findings. - FY2020-Q1RestatedAnnual report
「Based on these newly obtained findings, the company is conducting a Phase 1b clinical trial of the combination with an immune checkpoint inhibitor antibody.」
Based on findings from clinical and animal studies of CBP501, the company continues the Phase 1b trial of the combination with an immune checkpoint inhibitor antibody. - FY2019ReframedAnnual report
「Based on these findings, the company plans to make the combination the main focus of CBP501 development for the time being.」
The company repositioned the combination of CBP501, cisplatin and an immune checkpoint inhibitor antibody from one of the research and trial subjects to the main focus of CBP501 development for the time being. - FY2019-Q3AdvancedAnnual report
「The data from the dose-escalation phase suggested the potential of CBP501 and were presented at the American Association for Cancer Research (AACR) meeting held in Atlanta, US, from the end of March 2019.」
The company obtained data from the combination trial of CBP501 and an immune checkpoint inhibitor antibody and presented results suggesting its potential at the AACR meeting at the end of March 2019. - FY2019-Q2AdvancedAnnual report
「During the cumulative second-quarter period, the Company completed the dose-escalation phase, the first part of the Phase 1b trial, and, after carefully reviewing the results, began the expansion phase, the second part of the trial, for pancreatic and colorectal cancer.」
Development of the combination of CBP501 and an immune checkpoint inhibitor antibody progressed from the dose-escalation phase to the expansion phase for specific cancer types. - FY2019-Q1RestatedAnnual report
「Analysis of Phase 2 clinical trial data for CBP501 produced findings suggesting that the compound exhibits anticancer activity by acting through modulation of calmodulin function across various areas, including cancer immunity and the tumor microenvironment. The company also worked to obtain animal study data on combinations of CBP501 with platinum-based anticancer agents and immuno-oncology agents. Based on these newly obtained findings, the company is conducting a clinical trial, a Phase 1b trial, in combination with an immune checkpoint inhibitor antibody.」
The company continues research on combinations of CBP501, platinum-based anticancer agents and immuno-oncology agents, as well as the Phase 1b trial based on those findings. - FY2018-Q3RestatedAnnual report
「Analysis of Phase 2 clinical trial data for CBP501 produced findings suggesting that the compound exhibits anticancer activity by acting through modulation of calmodulin function across various areas, including cancer immunity and the tumor microenvironment. The company also worked to obtain animal study data on combinations of CBP501 with platinum-based anticancer agents and immuno-oncology agents.」
The company continues research to obtain animal study data and other information on combinations of CBP501, platinum-based anticancer agents and immuno-oncology agents, as well as the Phase 1b trial based on those findings. - FY2018-Q2RestatedAnnual report
「Analysis of Phase 2 clinical trial data for CBP501 produced findings suggesting that the compound exhibits anticancer activity by acting through modulation of calmodulin function across various areas, including cancer immunity and the tumor microenvironment. The company also worked to obtain animal study data on combinations of CBP501 with platinum-based anticancer agents and immuno-oncology agents.」
The company continues research to obtain animal study data and other information on combinations of CBP501, platinum-based anticancer agents and immuno-oncology agents, as well as the Phase 1b trial based on those findings. - FY2017AdvancedAnnual report
「Through the results of clinical trials conducted to date and detailed analyses of the data, the company obtained findings indicating that combining CBP501 and cisplatin with an immune checkpoint inhibitor antibody enhances efficacy.」
The company obtained findings and data indicating enhanced efficacy from the combination of CBP501, cisplatin and an immune checkpoint inhibitor antibody, and progressed to preparations for a Phase 1b trial. - FY2017-Q3RestatedAnnual report
「Analysis of Phase 2 clinical trial data for CBP501 produced findings suggesting that the compound exhibits anticancer activity by acting through modulation of calmodulin function across various areas, including cancer immunity and the tumor microenvironment. The company also worked to obtain animal study data on combinations of CBP501 with platinum-based anticancer agents and immuno-oncology agents.」
The company continues to obtain animal study data on combinations of CBP501, platinum-based anticancer agents and immuno-oncology agents. - FY2017-Q1First statedAnnual report
「The company also worked to obtain animal study data and other information on the combination of CBP501, platinum-based anticancer agents and immuno-oncology agents.」
The company is obtaining animal study data on combinations of CBP501 with platinum-based and immuno-oncology agents and is using the results as a basis for considering a Phase 1b trial and strategic partnerships.